Company Overview and News

1
HDFC Bank raises Rs8,500 crore by issuing equity to parent HDFC

2h livemint
New Delhi: HDFC Bank on Tuesday said it has raised Rs8,500 crore by issuing over 3.9 crore shares on preferential basis to its parent HDFC Ltd.
HDB 500180 HDFCBANK HDFC 500010 HDFC

1
HDFC Bank raises Rs 8,500 cr by issuing equity to parent HDFC

3h moneycontrol
HDFC Bank today said it has raised Rs 8,500 crore by issuing over 3.9 crore shares on preferential basis to its parent HDFC Ltd.
HDB 500180 HDFCBANK HDFC 500010 HDFC

1
HDFC AMC sets IPO price band at Rs 1,095-1,100

5h thehindubusinessline
HDFC Asset Management Company, the country’s second largest mutual fund firm, has fixed a price band of Rs 1,095-1,100 per share for its initial public offering, through which it is estimated to garner Rs 2,800 crore.
523405 SLFPF SL IIFL HDFC 532636 HDB 500180 HDFCBANK 500010 HDFC JMFINANCIL SLFPY

1
HDFC Bank Limited - Allotment of Securities

6h nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
HDB 500180 HDFCBANK

1
HDFC Bank Limited - Preferential issue

8h nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
HDB 500180 HDFCBANK

5
Sensex falls 218 pts, Nifty below 11k as WPI inflation races to 4-yr high

2018-07-16 freepressjournal.in
Mumbai: The benchmark BSE Sensex dropped by around 218 points or 0.60 per cent due to sell-off in banking, pharma, and metal stocks as investors turned cautious after wholesale inflation surged to a four-year high. The broad-based Nifty cracked below the 11,000-mark as 35 of its constituents closed in the red, led by Dr Reddy’s, Tata Steel and Lupin.
IBN HINDUNILVR BHRQY 533278 VEDL 532454 ICICIBANK 500470 TTST TATASTEEL TATLY HDB 532174 500180 500696 HDFCBANK 500570 BHARTIARTL TATAMOTORS CLNDY COALINDIA TTM

1
Farm loan waivers, not real income growth, driving rural revival: Report

2018-07-16 freepressjournal.in
Mumbai: The green-shoots of demand growth seen in some rural pockets is driven by farm loan waivers and not likely due to real increases in rural incomes and wages, indicative that the economy is still some time away from a full-blown rural revival, says a report.
HDB 500180 HDFCBANK

2
Few stocks rising from India selloff even as market hits record

2018-07-16 theedgemarkets
(July 16): India may be Asia’s best-performing major market this year, but not everyone is rejoicing the return of the nation’s benchmark gauges into record territory.
532540 500325 HDB 500180 RELIANCE RIGD HDFCBANK TCS TTNQY RLNIY

1
Market capitalisation of nine of top 10 most valued cos zoom Rs 1.58 lakh cr

2018-07-15 moneycontrol
Combined market capitalisation of nine of the 10 most valued companies surged by a whopping Rs 1,58,882.34 crore last week, helped by an overall strong broader market and smart surge in the valuation of Reliance Industries Ltd (RIL).
500325 KMBKY RELIANCE HINDUNILVR TTNQY MRZUY 532500 532540 HDB MARUTI 500180 RIGD KOTAKBANK 500696 HDFCBANK TCS 500247 RLNIY SBAZ

1
M-cap of nine of top 10 most valued firms zoom Rs 1.58 lakh cr

2018-07-15 thehindubusinessline
Over the last week, the Sensex recorded a significant rise of 883.77 points. File Photo - BusinessLine
500325 KMBKY RELIANCE HINDUNILVR TTNQY MRZUY 532500 532540 HDB MARUTI 500180 RIGD KOTAKBANK 500696 HDFCBANK TCS 500247 RLNIY SBAZ

1
Sensex slips from record on profit-booking

2018-07-13 freepressjournal.in
Mumbai: The BSE Sensex retreated from record high to end flat at 36,541.63 today in volatile trade as investors booked profit in recent gainers despite firm global cues.
BAJAJ-AUTO 500325 RELIANCE 532977 BHRQY 533278 532215 500470 AXISBANK RIGD HDFCBANK HEROMOTOCO BHARTIARTL CLNDY RLNIY YESBANK AXB IBN 532648 YYBKY AXBKY 500182 532454 AXBA ICICIBANK TTST TATASTEEL TATLY HDB 532174 500180 HRTQY COALINDIA

1
Reliance Industries market cap breaches Rs 7 lakh-cr mark

2018-07-13 moneycontrol
The market valuation of Reliance Industries today briefly surged past Rs 7 lakh crore mark, making it the second company after TCS to achieve this milestone. RIL's market capitalisation (m-cap) rose to Rs 7,01,404 crore (over USD 102 billion) in early trade on BSE.
532540 500325 HDB 500180 RELIANCE RIGD HDFCBANK TCS TTNQY RLNIY

1
An evening walk down Dalal Street | Nifty ends flat but holds 11K, Sensex gives up all of its gains

2018-07-13 moneycontrol
The market took a breather on last day of the week as benchmark indices closed in the red on Friday after rallying sharply in the previous session.
500325 500116 AXB IBN 532706 RELIANCE IDBI INOXLEISUR ICLQY 532822 532215 AXBKY AXBA ICICIBANK AXISBANK HDB 532174 500180 RIGD IDEA HDFCBANK RLNIY

1
NTPC signs Rs 1,500 crore term loan with HDFC Bank

2018-07-13 moneycontrol
NTPC, India's largest electricity generating company, today said it has signed a term loan agreement with HDFC Bank for availing a loan of Rs 1,500 crore. The 15-year loan will bear an interest rate linked to 3-months MCLR of the bank, the company said in a statement.
HDB 500180 HDFCBANK

1
RIL’s market capitalisation breaches Rs 7 lakh-cr mark, India’s 2nd company to achieve the mark after TCS

2018-07-13 freepressjournal.in
New Delhi: The market valuation of Reliance Industries today surged past Rs 7 lakh crore mark in the morning trade, making it the second company after TCS to achieve this milestone.
532540 500325 HDB 500180 RELIANCE RIGD TCS HDFCBANK TTNQY RLNIY

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

15h - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

17h - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...